Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Decibel Therapeutics stock

Own Decibel Therapeutics stock in just a few minutes.

Decibel Therapeutics, Inc is a biotechnology business based in the US. Decibel Therapeutics shares (DBTX) are listed on the NASDAQ and all prices are listed in US Dollars. Decibel Therapeutics employs 40 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Decibel Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – DBTX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Decibel Therapeutics share price

Use our graph to track the performance of DBTX stocks over time.

Decibel Therapeutics shares at a glance

Information last updated 2021-04-29.
52-week range$9.25 - $24.39
50-day moving average $11.85
200-day moving average $13.74
Wall St. target price$28.75
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Decibel Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Decibel Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Decibel Therapeutics financials

Gross profit TTM $0
Return on assets TTM -40.97%
Return on equity TTM -145.27%
Profit margin 0%
Book value N/A
Market capitalisation $235.8 million

TTM: trailing 12 months

Shorting Decibel Therapeutics shares

There are currently 581,341 Decibel Therapeutics shares held short by investors – that's known as Decibel Therapeutics's "short interest". This figure is 9% up from 533,498 last month.

There are a few different ways that this level of interest in shorting Decibel Therapeutics shares can be evaluated.

Decibel Therapeutics's "short interest ratio" (SIR)

Decibel Therapeutics's "short interest ratio" (SIR) is the quantity of Decibel Therapeutics shares currently shorted divided by the average quantity of Decibel Therapeutics shares traded daily (recently around 151786.1618799). Decibel Therapeutics's SIR currently stands at 3.83. In other words for every 100,000 Decibel Therapeutics shares traded daily on the market, roughly 3830 shares are currently held short.

To gain some more context, you can compare Decibel Therapeutics's short interest ratio against those of similar companies.

However Decibel Therapeutics's short interest can also be evaluated against the total number of Decibel Therapeutics shares, or, against the total number of tradable Decibel Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Decibel Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Decibel Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0373% of the tradable shares (for every 100,000 tradable Decibel Therapeutics shares, roughly 37 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Decibel Therapeutics.

Find out more about how you can short Decibel Therapeutics stock.

Decibel Therapeutics share dividends

We're not expecting Decibel Therapeutics to pay a dividend over the next 12 months.

Decibel Therapeutics overview

Decibel Therapeutics, Inc. , a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company's lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. It is also developing DB-ATO, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the inner ear; and DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site